MIL62 not checked

Beijing Mabworks Biotech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
9 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Phase 1b: Participants will receive intravenous (IV) infusions of MIL62 at doses of 500 mg or 1000 mg on Week (W) 1 Day (D) 1, W3D1, W25D1, W27D1, W53D1, W79D1, W105D1, W131D1, W157D1, W183D1, and W209D1. Participants initially assigned to the 500 mg dose group who exhibit good tolerance may be escalated to the 1000 mg dose starting from W25D1. Phase 3 (Randomised Controlled Period \[RCP\]):…”In the company’s words, NCT05314010 on ClinicalTrials.gov
Tested for
Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus, Lupus Nephritis
Main trialPhase 3
“This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.”In the company’s words, NCT05314010 on ClinicalTrials.gov

Other drugs for Neuromyelitis Optica Spectrum Disorder

All 10 drugs for Neuromyelitis Optica Spectrum Disorder

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 21 Feb 2025 A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3Recruiting Dec 2028 A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Phase 1/2Active, not recruiting 16 Jan 2025 Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis
Phase 3Unknown Mar 2025 MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Phase 3Unknown 13 May 2025 A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
Phase 2Completed 21 Nov 2024 A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Phase 1/2Unknown 9 Jan 2024 MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Phase 1/2Completed 4 Mar 2025 A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy
Phase 1Completed 30 May 2019 A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MIL62

Following is part of Solo: you see every change to MIL62 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in